Testosterone Replacement Therapy and Risk of Favorable and Aggressive Prostate Cancer - Stacy Loeb

May 31, 2017

(Length of discussion - 17 minutes)

Medical or surgical castration are currently the mainstay of therapy for advanced prostate cancer. However, there is controversy regarding the association between testosterone replacement therapy (TRT) and advanced prostate cancer risk. Studies on this have been done in the past and the data was combined in a meta-analysis concluding that there is no increased risk for advanced disease, however these studies were small with limited follow-up. Dr. Loeb and team re-visit this controversy using nationwide data from Sweden to gather further information on this drug safety study.

Alicia Morgans

Stacy Loeb, MD, is an Assistant Professor of Urology and Population Health at New York University (NYU), specializing in prostate cancer and men's health. She has a K07 grant from the National Cancer Institute to study active surveillance for prostate cancer, and a Young Investigator Award from the Prostate Cancer Foundation to study digital media in prostate cancer. Dr. Loeb is Chair of the Social Media Work Group of the American Urological Association, and participates actively in patient outreach as Chair of the Technology and Publications Committee for the Urology Care Foundation. She is also on the Editorial Board for the British Journal of Urology International, European Urology, Urology Practice, Nature Reviews Urology, Urology Times and Reviews in Urology.

Related Content:
Read the Abstract

Is using testosterone supplementation putting me at higher risk of prostate cancer?